Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Other Operating Expenses (2016 - 2025)

Collegium Pharmaceutical has reported Other Operating Expenses over the past 6 years, most recently at -$19000.0 for Q4 2025.

  • Quarterly results put Other Operating Expenses at -$19000.0 for Q4 2025, up 99.96% from a year ago — trailing twelve months through Dec 2025 was -$35.2 million (up 43.99% YoY), and the annual figure for FY2025 was -$5.4 million, up 66.05%.
  • Other Operating Expenses for Q4 2025 was -$19000.0 at Collegium Pharmaceutical, up from -$10.9 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for COLL hit a ceiling of $11.6 million in Q3 2023 and a floor of -$207.0 million in Q4 2023.
  • Median Other Operating Expenses over the past 3 years was -$9.4 million (2024), compared with a mean of -$29.3 million.
  • Peak annual rise in Other Operating Expenses hit 99.96% in 2025, while the deepest fall reached 302.67% in 2025.
  • Collegium Pharmaceutical's Other Operating Expenses stood at -$207.0 million in 2023, then soared by 74.99% to -$51.8 million in 2024, then skyrocketed by 99.96% to -$19000.0 in 2025.
  • The last three reported values for Other Operating Expenses were -$19000.0 (Q4 2025), -$10.9 million (Q3 2025), and -$10.2 million (Q2 2025) per Business Quant data.